157 related articles for article (PubMed ID: 38465406)
1. Antifungal drug resistance in Candida: a special emphasis on amphotericin B.
Ahmady L; Gothwal M; Mukkoli MM; Bari VK
APMIS; 2024 May; 132(5):291-316. PubMed ID: 38465406
[TBL] [Abstract][Full Text] [Related]
2. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
Madaan K; Bari VK
Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
4. Artemisinin elevates ergosterol levels of Candida albicans to synergise with amphotericin B against oral candidiasis.
Zhu C; Liao B; Ye X; Zhou Y; Chen X; Liao M; Cheng L; Zhou X; Ren B
Int J Antimicrob Agents; 2021 Sep; 58(3):106394. PubMed ID: 34197906
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and Antifungal Susceptibility of
Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
[TBL] [Abstract][Full Text] [Related]
6. Unmasking the Amphotericin B Resistance Mechanisms in
Silva LN; Oliveira SSC; Magalhães LB; Andrade Neto VV; Torres-Santos EC; Carvalho MDC; Pereira MD; Branquinha MH; Santos ALS
ACS Infect Dis; 2020 May; 6(5):1273-1282. PubMed ID: 32239912
[TBL] [Abstract][Full Text] [Related]
7. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.
Mesa-Arango AC; Trevijano-Contador N; Román E; Sánchez-Fresneda R; Casas C; Herrero E; Argüelles JC; Pla J; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2014 Nov; 58(11):6627-38. PubMed ID: 25155595
[TBL] [Abstract][Full Text] [Related]
8. [Neonatal Candida infections and the antifungal susceptibilities of the related Candida species].
Altuncu E; Bilgen H; Cerikçioğlu N; Ilki A; Ulger N; Bakır M; Akman I; Ozek E
Mikrobiyol Bul; 2010 Oct; 44(4):593-603. PubMed ID: 21063972
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections.
Esfahani A; Omran AN; Salehi Z; Shams-Ghahfarokhi M; Ghane M; Eybpoosh S; Razzaghi-Abyaneh M
Microb Pathog; 2022 Sep; 170():105696. PubMed ID: 35921954
[TBL] [Abstract][Full Text] [Related]
10. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
11. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
12. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
13. Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae.
Young LY; Hull CM; Heitman J
Antimicrob Agents Chemother; 2003 Sep; 47(9):2717-24. PubMed ID: 12936965
[TBL] [Abstract][Full Text] [Related]
14. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
15. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
Krcmery V; Barnes AJ
J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
[TBL] [Abstract][Full Text] [Related]
16. Surveillance Study of Epidemiology, Antifungal Susceptibility and Risk Factors of Invasive Candidiasis in Critically ill Patients.
Wang B; Wang Y; Zhang L; Lu F; Zhang M; Xu Y
Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704741
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and antifungal susceptibility of fungal infections from 2018 to 2021 in Shandong, eastern China: A report from the SPARSS program.
Wang M; Zhang C; Li Z; Ji B; Man S; Yi M; Li R; Hao M; Wang S
Indian J Med Microbiol; 2024; 47():100518. PubMed ID: 38016503
[TBL] [Abstract][Full Text] [Related]
18. Correlation between antifungal consumption and the distribution of Candida species in different hospital departments of a Lebanese medical Centre.
Awad L; Tamim H; Abdallah D; Salameh M; Mugharbil A; Jisr T; Zahran K; Droubi N; Ibrahim A; Moghnieh R
BMC Infect Dis; 2018 Nov; 18(1):589. PubMed ID: 30453891
[TBL] [Abstract][Full Text] [Related]
19. Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.
Vazquez JA; Arganoza MT; Boikov D; Yoon S; Sobel JD; Akins RA
J Clin Microbiol; 1998 Sep; 36(9):2690-5. PubMed ID: 9705415
[TBL] [Abstract][Full Text] [Related]
20. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
